Clarity on waiving multiple dose study [Regulatives / Guidelines]
The recently updated MR guideline (EMA/CPMP/EWP/280/96 Corr1) mentions about the possibility of waiving multiple dose study (593-595). However, 612-615 mentions that there isnt sufficient scientific evidence. With the current scenario, would waiving multiple dose study on the basis suggested in 593-595 be a risk? How can a generic company justify scientific evidence for this approach?
A multiple dose study is needed unless a single dose study has been performed with the highest strength which has demonstrated that the mean AUC(0-τ) after the first dose covers more than 90% of mean AUC(0-∞) for both test and reference, and consequently a low extent of accumulation is expected.612-615
The discussion of the opportunity of using equivalence in Cτ in single dose studies as basis for waiving the multiple dose study has been recognized. However, there is not considered to be sufficient scientific evidence at the moment to encourage this approach.
Thank the team in advance for clarification.
- Draft EMA MR formulations GL published! Ohlbe 2013-03-15 12:10 [Regulatives / Guidelines]
- Housekeeping suggestions Helmut 2013-03-15 13:28
- Scaling for pAUCs Helmut 2013-03-15 14:19
- Draft EMA MR formulations GL published! ioanam 2013-03-30 17:54
- Clarity on waiving multiple dose studyTina 2013-05-15 14:19
- SD vs. MD, partial AUCs Helmut 2013-06-21 19:24
- tmax (DR & multiphasic) Helmut 2013-06-22 01:15
- Presentations of the EUFEPS meeting Helmut 2013-07-15 15:50
- ⧫ Deadline approaching ⧫ Helmut 2013-08-16 16:41
- Download comment form Helmut 2013-08-26 11:28
- Food effect Compliance 2013-08-26 12:04
- Food effect Dr_Dan 2013-08-26 16:48
- Variability (MR vs. IR) Helmut 2013-09-12 15:23